Company news

GeoVax Labs, Inc. news in 2022

GeoVax Labs, Inc.'s news releases, calls and decks from 2022, newest first.

View company

GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

December 6, 2022

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

November 8, 2022

GeoVax Announces Addition to Its Board of Directors

August 31, 2022

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

August 2, 2022

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

July 27, 2022

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

July 25, 2022

GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development

June 12, 2022

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

May 24, 2022

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

May 23, 2022

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

April 26, 2022

GeoVax Announces Issuance of Cancer Vaccine Patent

March 21, 2022

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

March 13, 2022

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

March 8, 2022

GeoVax Announces Key Staff Appointments

March 6, 2022

GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update

February 22, 2022

GeoVax Announces Closing of $10 Million Private Placement

January 19, 2022

GeoVax Announces $10 Million Private Placement

January 13, 2022

GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

January 12, 2022

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

January 10, 2022

Calls in 2022

Decks in 2022